MYC and colorectal carcinoma: also detected the downregulation of c‐Myc expression after treatment with aprepitant in human CRC cells using a reverse phase protein array.[10a] Since c‐Myc is a master molecule of cell proliferation and survival,[13] we investigated whether c‐Myc downregulation mediated the cytotoxicity caused by treatment with NK‐1R antagonists.